Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States

References

• Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–795.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Cancer Statistics review: Non-Hodgkin Lymphoma. [Internet]. 2020; [cited 2020 Oct 1]. Available from: https://seer.cancer.gov/csr/1975_2016/results_merged/sect_19_nhl.pdf.
   Google Scholar
• The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget. 2017;8(68):112516–112529.
   PubMedGoogle Scholar
• Arcaini L, Lamy T, Walewski J, et al. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2018;180(2):224–235.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256–1269.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Skarbnik AP, Ma E, Lafeuille M-H, et al. Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices. Leuk Lymphoma. 2017;58(8):1968–1972.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24(11):2892–2897.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Zhang M-J, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32(4):273–281.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19(4):625–631.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. [Internet]. 2020; [cited 2020 Jul 22]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. FDA [Internet]. 2020; [cited 2020 Oct 9]; Available from: https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma.
   Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) [Internet]. clinicaltrials.gov. 2020; [cited 2020 Jul 22]. Report No.: NCT02601313. Available from: https://clinicaltrials.gov/ct2/show/NCT02601313.
   Google Scholar
• CDC. United States Life Tables. National Vital Statistics Reports. 2008. Vol. 61. No. 3.
   Google Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245.
   PubMed Web of Science ®Google Scholar
• ICER. CAR-T Therapies: Final Evidence Report [Internet]. ICER. 2018; [cited 2020 Aug 11]. Available from: https://icer-review.org/material/car-t-final-report/.
   Google Scholar
• Lambert PC, Dickman PW, Weston CL, et al. Estimating the cure fraction in population-based cancer studies by using finite mixture models. J Royal Stat Soc Ser C (App Stat). 2010;59(1):35–55.
   Web of Science ®Google Scholar
• Rutherford M, Lambert P, Sweeting M, et al. NICE DSU Technical Support Document 21. Flexible Methods for Survival Analysis. [Internet]. 2020; [cited 2020 Dec 14]. Available from: http://nicedsu.org.uk/.
   Google Scholar
• Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma. ASH; 2020. [cited 2020 Dec 14]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper136382.html.
   Google Scholar
• Centers for Medicare & Medicaid Services. 2020. ASP Drug Pricing Files [Internet]. 2020; [cited 2020 Aug 12]. Available from: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files.
   Google Scholar
• RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics/IBM Watson Health; 2020 [cited 2020 Aug 12]. Available from: https://www.micromedexsolutions.com
   Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:Supplement.
   Google Scholar
• Halpern NA, Goldman DA, Tan KS, et al. Trends in critical care beds and use among population groups and medicare and medicaid beneficiaries in the United States: 2000–2010. Crit Care Med. 2016;44(8):1490–1499.
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. Hospital adjusted expenses per inpatient day [Internet]. 2018; [cited 2020 Aug 12]. Available from: https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day/.
   Google Scholar
• Bennett MI, Ziegler L, Allsop M, et al. What determines duration of palliative care before death for patients with advanced disease? A retrospective cohort study of community and hospital palliative care provision in a large UK city. BMJ Open. 2016;6(12):e012576.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Hospice Services Payment System - Base payment rate for FY 2020 for days 1-60. [Internet]. 2019; [cited 2020 Aug 12]. Available from: http://medpac.gov/docs/default-source/payment-basics/medpac_payment_basics_19_hospice_final_sec.pdf.
   Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71.
   PubMed Web of Science ®Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. De Mello RA, editor. PLoS One. 2018;13(4):e0196007.
   PubMed Web of Science ®Google Scholar
• HCUPnet. Healthcare Cost and Utilization Project [Internet]. HCUPnet. 2020; [cited 2020 Aug 26]. Available from: https://hcupnet.ahrq.gov/#setup.
   Google Scholar
• Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370.
   PubMed Web of Science ®Google Scholar
• Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1–204.
   PubMed Web of Science ®Google Scholar
• NICE. Ibrutinib for treating relapsed or refractory mantle cell lymphoma. Technology appraisal guidance [TA502] - Committee Papers [Internet]. 2016. [cited 2020 Oct 1]. Available from: https://www.nice.org.uk/guidance/ta502/documents/committee-papers.
   Google Scholar
• Pickard AS, Law EH, Jiang R, et al. United states valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941.
   PubMed Web of Science ®Google Scholar
• NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies [Internet]. NICE; 2018; [cited 2020 Aug 12]. Available from: https://www.nice.org.uk/guidance/TA559.
   Google Scholar
• ICER. 2020. Value Assessment Framework: Final Framework [Internet]. 2020; [cited 2020 Aug 12]. Available from: https://icer-review.org/material/2020-value-assessment-framework-final-framework/.
   Google Scholar
• Hettle R, Corbett M, Hinde S, et al. Review of cost-effectiveness evidence for chimeric antigen receptor T-cell therapy and other interventions for acute lymphocytic leukaemia [Internet]. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. NIHR Journals Library. 2017; [cited 2020 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK424721/.
   Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719–726.
   PubMedGoogle Scholar
• Liu R, Snider JT, Diakite I, et al. Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucal (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US. EHA library; 06/12/20; 294211; EP1731 [Internet]. 2020; [cited 2020 Oct 7]. Available from: https://library.ehaweb.org/eha/2020/eha25th/294211/julia.thornton.snide.cost.effectiveness.of.axicabtagene.ciloleucel.28axi-cel29.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1766%2Aot_id%3D23248%2Afeatured%3D16775.
   Google Scholar
• Othus M, Barlogie B, LeBlanc ML, et al. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18(14):3731–3736.
   PubMed Web of Science ®Google Scholar
• Yu B, Tiwari RC, Cronin KA, et al. Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med. 2004;23(11):1733–1747.
   PubMed Web of Science ®Google Scholar
• Othus M, Li Y, Tiwari RC. A class of semiparametric mixture cure survival models with dependent censoring. J Am Stat Assoc. 2009;104(487):1241–1250.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models. Med Decis Making. 2019;39(3):294–298.
   PubMed Web of Science ®Google Scholar